Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
5-fluorouracil plus irinotecan chemoradiotherapy followed by chemotherapy for rectal cancer with resectable synchronous metastases
2007-004053-28Phase 2Active
- Sponsor
- Istituto Oncologico Veneto
- Start
- Nov 2007
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics, Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of fluorouracil, irinotecan, bevacizumab, cetuximab and levoleucovorin in rectal cancer, sponsored by Istituto Oncologico Veneto. Primary endpoints: Primary tumor downstaging response rate, Sphincter-saving rate and 1 more. Started Nov 2007; status: active.
02
Drugs
fluorouracilirinotecanbevacizumabcetuximablevoleucovorin
03
Conditions
rectal cancer
Beyond the preview
Go deeper on 2007-004053-28.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2007-004053-28.